Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 1;49(13):7476–7491. doi: 10.1093/nar/gkab540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — Loss of CCNC is important for survival and PARPi sensitivity in BRCA2-deficient Cells. (A) Validation of CCNC KO in HEK293A BRCA2 mAID-EGFP KI cells by western blot using the indicated antibodies. (B) Results of long-term clonogenic assays conducted using HEK293A BRCA2 mAID-EGFP CCNC-WT and -KO cells with the indicated treatments. Ola: Olaparib. (C) Quantification of relative cell survival in the clonogenic assays in (B). All treated groups were normalized to the indicated untreated group. The data are presented as means ± SD. ***P < 0.001 (Student's t-test). (D) Results of long-term clonogenic assays conducted using HEK293A BRCA2 mAID-EGFP CCNC-WT and -KO cells with the indicated treatments. Tal: Talazoparib. (E) Quantification of relative cell survival in the clonogenic assays in (D). All treated groups were normalized to the indicated untreated group. The data are presented as means ± SD. ***P < 0.001 (Student's t-test). (F) Capan-1 cells were infected with control pLentiCRISPRv2 (Lenti V2), or CCNC gRNA-1 (g1) virus and selected with puromycin. Western blot was conducted to validate CCNC knock down efficiency with the indicated antibodies. (G) Results of long-term clonogenic assays conducted using Capan-1 LentiV2 and CCNC g1 cells with different concentration of Olaparib treatments. Ola: Olaparib. (H) Quantification of relative cell survival in clonogenic assays in (G). All treated groups were normalized to the indicated untreated group. The data are presented as means ± SD. ***P < 0.001 (Student's t-test). (I) Results of long-term clonogenic assays conducted using Capan-1 LentiV2 and CCNC g1 cells with different concentration of Talazoparib treatments. Tal: Talazoparib. (J) Quantification of relative cell survival in the clonogenic assays in (I). All treated groups were normalized to the indicated untreated group. The data are presented as means ± SD. **P < 0.01, ***P < 0.001 (Student's t-test).